Package Leaflet: Information for the User
Combinest PF 50 micrograms/ml + 5 mg/ml eye drops, solution
Latanoprost/timolol
Read this package leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the package leaflet
This medicine contains two active substances: latanoprost and timolol. Latanoprost belongs to a group of medicines known as prostaglandin analogues. Timolol belongs to a group of medicines called beta-blockers. Latanoprost works by increasing the natural outflow of fluid from the eye into the bloodstream. Timolol works by reducing the production of fluid in the eye.
This medicine is used to reduce the pressure in the eye in case you have diseases known as open-angle glaucoma or ocular hypertension. Both of these diseases are related to an increase in pressure within the eye, which can eventually affect your vision. Your doctor will normally prescribe this medicine when other medicines have not worked adequately.
This medicine can be used in adult men and women (including the elderly), but it is not recommended for use in children and adolescents under 18 years of age.
This medicine is a sterile solution that does not contain preservatives.
Do not use Combinest PF:
Warnings and precautions
Talk to your doctor or pharmacist before you start using this medicine, if you have or have had in the past:
Tell your doctor that you are using this medicine before undergoing surgery, as timolol may affect the effects of some medicines used during anesthesia.
Children and adolescents
This medicine is not recommended for use in children and adolescents under 18 years of age.
Other medicines and Combinest PF
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines, including eye drops and medicines obtained without a prescription.
This medicine may affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma. Tell your doctor if you are using or plan to use medicines to lower blood pressure, heart medicines or medicines to treat diabetes.
In particular, consult your doctor or pharmacist if you are taking any of the following types of medicines:
Using Combinest PF with food and drink
Normal meals, food and drink have no effect on when or how you should use this medicine.
Pregnancy, breast-feeding and fertility
Pregnancy
Do not use this medicine if you are pregnant unless your doctor considers it necessary. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Breast-feeding
Do not use this medicine if you are breast-feeding. This medicine may pass into breast milk. Ask your doctor for advice before taking any medicine during breast-feeding.
Fertility
In animal studies, latanoprost and timolol have not been found to have any effect on male or female fertility.
Driving and using machines
When using this medicine, you may experience blurred vision for a short period of time. If this happens, do not drive or use tools or machines until your vision is clear again.
Combinest PF containsmacrogolglycerol hydroxystearate 40
This medicine contains macrogolglycerol hydroxystearate 40, which may cause skin reactions.
Combinest PF containsphosphate buffer
This medicine contains 6.54 mg of phosphates in each ml of solution.
If you have severe damage to the clear layer on the front of the eye (cornea), treatment with phosphates, in very rare cases, may cause blurred vision due to calcium deposits.
Use in athletes
This medicine contains timolol, which may produce a positive result in doping tests.
Follow the instructions for administration given by your doctor or pharmacist. Ask your doctor or pharmacist if you have any questions.
The recommended dose for adults (including elderly patients) is one drop once daily in the affected eye(s).
Do not use this medicine more than once a day, as the effectiveness of the treatment may decrease if it is administered more frequently.
Use this medicine as your doctor has told you. Continue using it until your doctor tells you to stop.
Your doctor may want to perform additional heart and circulatory tests if you are using this medicine.
Contact lens users
If you use contact lenses, you should remove them before using this medicine. After applying this medicine, wait 15 minutes before putting your contact lenses back in.
Instructions for use
1a 1b |
|
|
|
3 |
|
4 |
|
5 |
|
2.5 ml
5 ml
|
If you use Combinest PF with other eye drops
Wait at least 5 minutes between the application of this medicine and the administration of other eye drops.
If you use more Combinest PF than you should
If you have applied more drops in the eye than you should, you may feel a slight irritation in the eye and your eyes may also become red and watery. This should go away, but if you are concerned, contact your doctor.
If you swallow Combinest PF
In case of accidental ingestion of this medicine, consult your doctor or call the Toxicology Information Service, telephone: 91 562 04 20. If you swallow a large amount of this medicine, you may feel unwell, have stomach pain, feel tired, hot, dizzy and start sweating.
If you forget to use Combinest PF
Continue with the next dose as usual. Do not use a double dose to make up for the forgotten dose. If you have any doubts, consult your doctor or pharmacist.
If you have any doubts about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
You can continue using the eye drops as usual, unless the adverse effects are severe. If you are concerned, consult your doctor or pharmacist. Do not stop using this medicine without consulting your doctor.
The following are known adverse effects associated with the use of eye drops containing the active substances latanoprost and timolol. The most important adverse effect is the possibility of a gradual and permanent change in eye color. It is also possible that eye drops containing the active substances latanoprost and timolol may cause serious changes in the way the heart works. If you notice any change in heart rate or cardiac function, you should consult your doctor and tell them that you have been using this medicine.
The following adverse effects have been observed with the use of eye drops containing the active substances latanoprost and timolol:
Very Common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Other Adverse Effects
Like other medicines used in the eyes, latanoprost and timolol are absorbed into the bloodstream. The incidence of adverse effects after using eye drops is lower than when medicines are taken orally or injected.
Although not seen with eye drops containing both active substances latanoprost and timolol, the following adverse effects have been observed with one of the components of this medicine and may therefore occur with the use of this medicine. The adverse effects listed include reactions observed within the group of beta-blockers (e.g., timolol) when used to treat eye conditions:
In very rare cases, some patients with severe damage to the front transparent part of the eye (cornea) have developed cloudy areas in the cornea due to calcium deposits produced during treatment.
Reporting Adverse Effects:
If you experience any adverse effects, consult your doctor, even if they are possible adverse effects that are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es
By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton and bottle after CAD. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
2.5 ml
You must discard each bottle after 4 weeks of first opening, to prevent infections. Write the date of opening on the carton in the space provided.
5 ml
You must discard each bottle after 8 weeks of first opening, to prevent infections. Write the date of opening on the carton in the space provided.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicines in the pharmacy's SIGRE point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Combinest PF Composition
Each ml of solution contains 50 micrograms of latanoprost and 5 mg of timolol (as 6.8 mg of timolol maleate).
Appearance and Package Contents
2.5 ml
Combinest PF eye drops solution is a clear, colorless, and particle-free aqueous solution of 2.5 ml.
It is marketed in a carton, which contains a 5 ml multidose bottle (HDPE) with a pump (PP, HDPE, LDPE) and a green or orange pressure cylinder and cap (HDPE).
5 ml
Combinest PF eye drops solution is a clear, colorless, and particle-free aqueous solution of 5 ml.
It is marketed in a carton, which contains a 5 ml multidose bottle (HDPE) with a pump (PP, HDPE, LDPE) and a green or orange pressure cylinder and cap (HDPE).
Package sizes: Carton with 1 or 3 bottles of 2.5 ml solution or 1 or 3 bottles of 5 ml solution.
Not all package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Esteve Pharmaceuticals, S.A.
Passeig de la Zona Franca, 109
08038 Barcelona
Spain
Manufacturer
Lomapharm GmbH
Langes Feld 5
31860 Emmerthal
Germany
or
Pharmathen S.A.
Dervenakion Str. 6
Pallini 15351
Attiki
Greece
This medicine is authorized in the Member States of the European Economic Area under the following names:
Name | Country |
Latanoprost/Timolol Pharmathen | Denmark, France, Belgium, Germany, Austria, Slovenia |
Lonata | Cyprus, Greece |
Latanoprost e Timololo Pharmathen | Italy |
COMBINEST PF | Spain |
Latanotim | Netherlands |
Date of Last Revision of this Leaflet:March 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/